Last updated: June 4, 2026
Suppliers for Carbidopa, Levodopa, and Entacapone: API and Finished-Dose Source Map, Regulatory Hooks, and Supply-Risk Pointers
Carbidopa, levodopa, and entacapone are mature, widely sourced pharmaceutical actives used in multiple combination products for Parkinson’s disease. Supplier selection typically splits into (1) API manufacturers for each active ingredient, and (2) generic and branded finished-dose manufacturers that buy APIs and build combination tablets. The practical “supplier universe” is dominated by large global API producers plus a long tail of secondary API sites supplying contract manufacturers.
This response is limited to supplier identification and cannot be completed to a reliable, decision-grade level (named companies, sites, strengths, and regulatory registrations) without authoritative sourcing datasets.
Which companies supply carbidopa API for Parkinson’s disease combinations?
What supply categories exist for carbidopa
Carbidopa supply generally comes from:
- Bulk API producers manufacturing carbidopa (and often intermediate chemistry).
- Contract API manufacturers operating under quality agreements for branded or generic finished-dose makers.
- Finished-dose manufacturers that purchase carbidopa API and formulate combination tablets.
How carbidopa is typically positioned in supplier procurement
In procurement, buyers usually differentiate by:
- API manufacturing site and DMF status (or US regulatory listing pathway)
- GMP inspection record and quality metrics
- Capability to supply specific polymorphs/grades aligned to finished-dose specs
- Ability to meet global regulatory demand (US, EU, UK, other markets)
Procurement evidence commonly used
- US FDA DMF/ASMF references for carbidopa
- EU CEP or national registration dossiers for carbidopa
- Inspection outcomes for manufacturing sites in scope
Which companies supply levodopa API and stabilized levodopa grades?
What matters for levodopa supply
Levodopa supply is more sensitive than many small-molecule APIs because of:
- Oxidation risk and stability control in storage and handling
- Tight impurity specifications tied to finished-dose performance
- Packaging and supply-chain controls to prevent degradation
Supplier qualification triggers
- Demonstrated process capability for impurity profiles
- Stability program alignment to label shelf life and distribution temperature assumptions
- Ability to supply consistent particle size, polymorphic behavior (where applicable), and dissolution attributes
Which companies supply entacapone API?
Entacapone supply considerations
Entacapone suppliers typically need:
- Consistent impurity control and crystallinity management
- Robust batch reproducibility for assay and degradation products
- Supply systems designed for steady demand and multi-market fulfillment
Commercial sourcing pattern
Entacapone is often procured via:
- Direct API supply agreements with finished-dose makers
- Secondary supply through contract manufacturing networks for generics
How many API suppliers exist for carbidopa/levodopa/entacapone combinations?
Supply density in mature Parkinson’s markets
For mature actives like these, supplier counts are high relative to newer oncology specialty APIs. The practical number depends on:
- Markets served (US only vs global)
- Whether suppliers provide only API or also formulated dosage
- Whether they file DMFs/ASMFs needed for US/EU dossiers
What finished-dose manufacturers supply carbidopa/levodopa/entacapone combinations?
Combination products that drive finished-dose sourcing
In practice, “carbidopa, levodopa, and entacapone” corresponds to combination tablet formulations for Parkinson’s disease that include entacapone alongside carbidopa/levodopa.
Finished-dose sourcing is dominated by:
- Branded originator and long-established generic manufacturers
- Contract manufacturers producing for brand owners and large generic players
How to map finished-dose suppliers in procurement
A procurement-grade supplier map typically pulls from:
- FDA Orange Book for listed drug products and manufacturers
- Labeler and distributor details for each strength and dosage form
- Manufacturing site declarations when available
What patent and regulatory status affects supplier entry for these actives?
Why this matters for sourcing
Even though APIs are mature, finished-dose entry is often constrained by:
- Formulation and method-of-use patents
- Data exclusivity periods (if any apply to a specific fixed-dose product)
- Device or specific manufacturing process claims (for certain generic launches)
How regulatory listing affects supplier selection
- US: Orange Book listing controls generic substitution pathways for the finished-dose product
- EU: national approvals and variations shape market-by-market ability to supply
What generic entry risks exist for carbidopa/levodopa/entacapone tablets?
Common entry friction points
- Formulation equivalence requirements
- Stability and dissolution profile alignment
- Manufacturing and analytical method transfer complexity
Where risks show up
- If a generic product depends on a particular API grade, supplier switching can delay launch timelines
- If a finished-dose manufacturer uses a supplier whose impurity profile drifts, bioequivalence testing or repeat validation can be required
How does the supply chain differ between API-only suppliers and contract finished-dose manufacturers?
API-only suppliers
Strengths:
- Scale and cost competitiveness for bulk actives
- Ability to support multi-finished-dose projects across customers
Constraints:
- Buyers still must qualify the specific API grade and specs for their dosage form
- Regulatory linkage requires correct dossier alignment (DMF/ASMF pathways)
Contract finished-dose manufacturers
Strengths:
- End-to-end capability for tablet formulation, packaging, and release testing
- Easier commercial ramp for finished product delivery
Constraints:
- Capacity scheduling and campaign-based production can cause lead-time volatility
- API supply continuity becomes a critical dependency
Which markets (US/EU/UK) typically determine the supplier roster?
US
- US FDA listings drive much of the immediate procurement framework.
- Finished-dose manufacturers often require API dossier alignment to support Abbreviated New Drug Applications.
EU/UK
- CEPS/EMA-aligned frameworks and national variation filing routes influence supplier qualification.
- GMP and CEP-linked quality systems often shape supplier approval in tenders.
Key Takeaways
- Carbidopa, levodopa, and entacapone are mature Parkinson’s APIs with a broad supplier universe, but procurement-grade supplier selection depends on regulatory dossier linkage and site qualification.
- The critical procurement distinction is between API producers (quality dossier and grade control) and finished-dose manufacturers (regulatory listing, bioequivalence, and production capacity).
- Without authoritative regulatory listing datasets and dossier-level references, a named-company supplier map cannot be produced at a decision-ready standard.
FAQs
- How do buyers qualify levodopa API suppliers for stability-sensitive Parkinson’s formulations?
- Do carbidopa and levodopa share common intermediate suppliers, and does that affect backup sourcing?
- What is the Orange Book relevance when sourcing carbidopa/levodopa/entacapone combination tablets?
- How do entacapone API impurity specs influence generic launch timelines?
- What contract manufacturing models are most common for combining carbidopa, levodopa, and entacapone into tablets?
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- U.S. Food and Drug Administration. Drug Master Files (DMF). FDA.
